Literature DB >> 20812237

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Christopher T Harp1, Sara Ireland, Laurie S Davis, Gina Remington, Bonnie Cassidy, Petra D Cravens, Olaf Stuve, Amy E Lovett-Racke, Todd N Eagar, Benjamin M Greenberg, Michael K Racke, Lindsay G Cowell, Nitin J Karandikar, Elliot M Frohman, Nancy L Monson.   

Abstract

Recent evidence suggests that B- and T-cell interactions may be paramount in relapsing-remitting MS (RRMS) disease pathogenesis. We hypothesized that memory B-cell pools from RRMS patients may specifically harbor a subset of potent neuro-APC that support neuro-Ag reactive T-cell proliferation and cytokine secretion. To test this hypothesis, we compared CD80 and HLA-DR expression, IL-10 and lymphotoxin-α secretion, neuro-Ag binding capacity, and neuro-Ag presentation by memory B cells from RRMS patients to naïve B cells from RRMS patients and to memory and naïve B cells from healthy donors (HD). We identified memory B cells from some RRMS patients that elicited CD4(+) T-cell proliferation and IFN-γ secretion in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Notwithstanding the fact that the phenotypic parameters that promote efficient Ag presentation were observed to be similar between RRMS and HD memory B cells, a corresponding capability to elicit CD4(+) T-cell proliferation in response to myelin basic protein and myelin oligodendrocyte glycoprotein was not observed in HD memory B cells. Our results demonstrate for the first time that the memory B-cell pool in RRMS harbors neuro-Ag specific B cells that can activate T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812237      PMCID: PMC3072802          DOI: 10.1002/eji.201040516

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  70 in total

1.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

2.  Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Authors:  Amit Bar-Or; Lama Fawaz; Boli Fan; Peter J Darlington; Aja Rieger; Christine Ghorayeb; Peter A Calabresi; Emmanuelle Waubant; Stephen L Hauser; Jiameng Zhang; Craig H Smith
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

3.  Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis.

Authors:  Jorge Correale; Andrés Villa
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

4.  Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis.

Authors:  Zuzana Mikulkova; Petra Praksova; Pavel Stourac; Josef Bednarik; Lucie Strajtova; Rita Pacasova; Jana Belobradkova; Petr Dite; Jaroslav Michalek
Journal:  Cell Immunol       Date:  2010-02-06       Impact factor: 4.868

5.  Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Anna L Travelstead; Jerry A Colliver
Journal:  J Clin Immunol       Date:  2009-10-17       Impact factor: 8.317

6.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

7.  Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis.

Authors:  Christopher T Harp; Amy E Lovett-Racke; Michael K Racke; Elliot M Frohman; Nancy L Monson
Journal:  Clin Immunol       Date:  2008-07-02       Impact factor: 3.969

Review 8.  Antigen-specific B cell detection reagents: use and quality control.

Authors:  M Anthony Moody; Barton F Haynes
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

9.  Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Authors:  M Krumbholz; I Meinl; T Kümpfel; R Hohlfeld; E Meinl
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

10.  Helminth infections associated with multiple sclerosis induce regulatory B cells.

Authors:  Jorge Correale; Mauricio Farez; Gabriela Razzitte
Journal:  Ann Neurol       Date:  2008-08       Impact factor: 10.422

View more
  49 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 2.  B cells in multiple sclerosis: connecting the dots.

Authors:  H-Christian von Büdingen; Amit Bar-Or; Scott S Zamvil
Journal:  Curr Opin Immunol       Date:  2011-10-07       Impact factor: 7.486

3.  The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

Authors:  Sara J Ireland; Alyssa A Guzman; Dina E O'Brien; Samuel Hughes; Benjamin Greenberg; Angela Flores; Donna Graves; Gina Remington; Elliot M Frohman; Laurie S Davis; Nancy L Monson
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

Review 4.  Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

Authors:  H-Christian von Büdingen; Arumugam Palanichamy; Klaus Lehmann-Horn; Brady A Michel; Scott S Zamvil
Journal:  Eur Neurol       Date:  2015-03-25       Impact factor: 1.710

Review 5.  Circulating immune cells in multiple sclerosis.

Authors:  A P Jones; A G Kermode; R M Lucas; W M Carroll; D Nolan; P H Hart
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

Review 6.  Novel therapies for memory cells in autoimmune diseases.

Authors:  P Bhargava; P A Calabresi
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

7.  CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.

Authors:  Ding Chen; Sara J Ireland; Gina Remington; Enrique Alvarez; Michael K Racke; Benjamin Greenberg; Elliot M Frohman; Nancy L Monson
Journal:  J Immunol       Date:  2016-10-26       Impact factor: 5.422

Review 8.  Reprogramming of B cells into regulatory cells with engineered fusokines.

Authors:  Jiusheng Deng; Jacques Galipeau
Journal:  Infect Disord Drug Targets       Date:  2012-06

9.  Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis.

Authors:  Latt Latt Aung; Konstantin E Balashov
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

Review 10.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.